Latest News

• 3-6 June 2019
  Oncostellae expands partnering activities for OST-122 at the 2019 BIO Int’l Convention in Philadelphia
• 10 Dec 2018
  GI-restricted Jak3/Tyk2 inhibitor OST-122 well tolerated in clinical phase Ia study
  
  
• 23 Jul 2018
  Oncostellae initiated clinical development of OST-122